Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anosys
Epimmune announces termination of merger agreement
September 10th, 2003
Epimmune, Inc., (EPMN) announced that the merger agreement between Epimmune and Anosys has terminated. The companies concluded that conditions did not support the concept of the combined company. Epimmune has engaged a financial advisor to explore strategic alternatives for Epimmune. Epimmune, based in San Diego, California, is focused on the development of pharmaceutical products using multiple epitopes to specifically activate the body's immune system. Epimmune's therapeutic drug candidates have been designed to treat disease by stimulating the body's immune system to respond aggressively to infections such as HIV, hepatitis C...
Source: Biotech Week (2003-09-10)
|
